Tuberculosis (TB) Drugs Market: Information by Disease Type (Active TB, Latent TB), Therapy (First-Line, Second-Line) and Regional Outlook - Forecast Till 2026

May 21, 2019   Global Statistics Representing Tuberculosis (TB) Drugs Market Scenario Tuberculosis is caused by the Mycobacterium tuberculosis bacterium. It spreads when a person with active TB coughs or sneezes and the bacteria come in contact with a healthy person. A weakened immune system is the key cause of tuberculosis prevalence. According to the Central for Diseases Control and Prevention, around one-fourth of the world's population is infected with TB. Further, TB is a va...
Request Free Sample Report

Table Of Content

TABLE OF CONTENTS

1          Introduction

1.1       Market Definition

1.2       Market Scope

2          Research Methodology

2.1       Primary Research

2.2       Research Methodology

2.3       Assumptions & Exclusions

2.4       Secondary Data Sources

3          Market Overview

3.1       Report Segmentation & Scope

3.2       Value Chain Analysis: Tuberculosis Drugs Market

3.3       Key Market Trends

3.3.1    Drivers

3.3.2    Restraints

3.3.3    Opportunities

3.4       Porter’s Five Forces Analysis

3.4.1    Bargaining Power of Suppliers

3.4.2    Bargaining Power of Buyers

3.4.3    Threat of Substitution

3.4.4    Threat of New Entrants

3.4.5    Competitive Rivalry

3.5       Market Share Analysis

4          By Disease Type Overview

4.1       Introduction

4.1.1    Market Size & Forecast (Value)

4.2       Active TB

4.3       Latent TB

5          By Therapy

5.1       Introduction

5.1.1    Market Size & Forecast (Value)

5.2       First-Line Therapy

5.3       Second-Line Therapy

6          Regional Overview

6.1       Introduction

6.1.1    Market Size & Forecast (Value)

6.2       America

6.2.1    North America

6.2.1.1 U.S.

6.2.1.1.1          By Disease Type

6.2.1.1.2          By Therapy

6.2.1.2 Canada

6.2.1.2.1          By Disease Type

6.2.1.2.2          By Therapy

6.2.1.3 Mexico

6.2.1.3.1          By Disease Type

6.2.1.3.2          By Therapy

6.2.2    Latin America

6.2.2.1 By Disease Type

6.2.2.2 By Therapy

6.3       Europe

6.3.1    Market Size & Forecast (Value)

6.3.2    Germany

6.3.2.1 By Disease Type

6.3.2.2 By Therapy

6.3.3    France

6.3.3.1 By Disease Type

6.3.3.2 By Therapy

6.3.4    U.K.

6.3.4.1 By Disease Type

6.3.4.2 By Therapy

6.3.5    Italy

6.3.5.1 By Disease Type

6.3.5.2 By Therapy

6.3.6    Spain

6.3.6.1 By Disease Type

6.3.6.2 By Therapy

6.3.7    Rest of Europe

6.3.7.1 By Disease Type

6.3.7.2 By Therapy

6.4       Asia Pacific

6.4.1    Market Size & Forecast (Value)

6.4.2    Japan

6.4.2.1 By Disease Type

6.4.2.2 By Therapy

6.4.3    China

6.4.3.1 By Disease Type

6.4.3.2 By Therapy

6.4.4    Australia

6.4.4.1 By Disease Type

6.4.4.2 By Therapy

6.4.5    India

6.4.5.1 By Disease Type

6.4.5.2 By Therapy

6.4.6    South Korea

6.4.6.1 By Disease Type

6.4.6.2 By Therapy

6.4.7    Rest of Asia-Pacific

6.4.7.1 By Disease Type

6.4.7.2 By Therapy

6.5       Middle East & Africa

6.5.1    Market Size & Forecast (Value)

6.5.2    Saudi Arabia

6.5.2.1 By Disease Type

6.5.2.2 By Therapy

6.5.3    South Africa

6.5.3.1 By Disease Type

6.5.3.2 By Therapy

6.5.4    Kuwait

6.5.4.1 By Disease Type

6.5.4.2 By Therapy

6.5.5    Rest of Middle East & Africa

6.5.5.1 By Disease Type

6.5.5.2 By Therapy

7.         Company Profile

7.1       Sigma Pharmaceutical Pty Limited

7.1.1    Company Overview

7.1.2    Financial Performance

7.1.3    Recent Developments

7.1.4    Product Portfolio

7.2       Aventis Pharmaceuticals Limited

7.2.1    Company Overview

7.2.2    Financial Performance

7.2.3    Recent Developments

7.2.4    Product Portfolio

7.3       Integra Lifesciences Corporation

7.3.1    Company Overview

7.3.2    Financial Performance

7.3.3    Recent Developments

7.3.4    Product Portfolio

7.4       Aventis Pharmaceuticals Limited

7.4.1    Company Overview

7.4.2    Financial Performance

7.4.3    Recent Developments

7.4.4    Product Portfolio

7.5       Novartis AG

7.5.1    Company Overview

7.5.2    Financial Performance

7.5.3    Recent Developments

7.5.4    Product Portfolio

7.6       Sanofi -Aventis U.S. LLC

7.6.1    Company Overview

7.6.2    Financial Performance

7.6.3    Recent Developments

7.6.4    Product Portfolio

7.7       Hoffmann-La Roche Ltd

7.7.1    Company Overview

7.7.2    Financial Performance

7.7.3    Recent Developments

7.7.4    Product Portfolio

7.8       Bayer Health care

7.8.1    Company Overview

7.8.2    Financial Performance

7.8.3    Recent Developments

7.8.4    Product Portfolio

7.9       Versa pharma Incorporated,

7.9.1    Company Overview

7.9.2    Financial Performance

7.9.3    Recent Developments

7.9.4    Product Portfolio